CVS 2018 Formulary: Outcomes-Based Contracts In Oncology, Obesity, COPD

And for diabetes, Jardiance is out and Invokana is in; CVS formulary update includes far fewer exclusions than previous years and reinstates coverage for several drugs, signaling more muted approach to management.

shelves

CVS Health Corp.'s 2018 formulary strategy includes shifts in coverage for some prominent diabetes drugs, resumes coverage for a number of drugs previously excluded, and introduces a focus on outcomes-based contracts in oncology, obesity and COPD.

As part of the 2018 strategy, which was publicly announced Aug. 2, the pharmacy benefit manager will exclude...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Pricing Debate

More from Market Access